The pharmaceutical industry has suggested that it is difficult to review and predict the criteria for selecting evaluation targets as the targets for benefit revaluation were disclosed in the current year during the pilot project of Choline alfoscerate and Bilberry Fruit Dried Ext, Avocado-Soya, Ginkgo Leaf Ext, Silymarin, and Vitis Vinifera.
In response, The HIRA held a meeting with the pharmaceutical industry on December 23 last year to set standards for the ingredients subject to re-evaluation after discussing the ingredients and standards required for evaluation through expert advisory meetings since September last year.

Jang Yong-myung, executive director of HIRA Development, said at the Kor